vs
Coherus Oncology, Inc.（CHRS）与Rent the Runway, Inc.（RENT）财务数据对比。点击上方公司名可切换其他公司
Coherus Oncology, Inc.的季度营收约是Rent the Runway, Inc.的1.2倍（$12.7M vs $10.6M），Rent the Runway, Inc.净利率更高（721.7% vs -295.3%，领先1017.0%），Coherus Oncology, Inc.同比增速更快（64.9% vs 10.4%），过去两年Rent the Runway, Inc.的营收复合增速更高（1.0% vs -47.0%）
Coherus Oncology是一家处于商业化阶段的生物制药企业，专注于肿瘤领域药物的研发、生产与商业化，产品包括肿瘤生物类似药、新型靶向免疫肿瘤疗法，主要面向北美市场，致力于提升癌症患者平价创新治疗方案的可及性。
Rent the Runway Inc.是总部位于纽约的美国电商平台，由珍妮弗·海曼与珍妮弗·弗莱斯于2009年11月创立，主打设计师品牌服饰与配饰的租赁、订阅以及购买服务，是设计师服饰共享租赁模式的开创平台之一。
CHRS vs RENT — 直观对比
营收规模更大
CHRS
是对方的1.2倍
$10.6M
营收增速更快
CHRS
高出54.4%
10.4%
净利率更高
RENT
高出1017.0%
-295.3%
两年增速更快
RENT
近两年复合增速
-47.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $12.7M | $10.6M |
| 净利润 | $-37.6M | $76.5M |
| 毛利率 | 68.3% | -126.4% |
| 营业利润率 | -359.9% | -152.8% |
| 净利率 | -295.3% | 721.7% |
| 营收同比 | 64.9% | 10.4% |
| 净利润同比 | 25.7% | 504.8% |
| 每股收益（稀释后） | $-0.34 | $13.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHRSRENT
| Q4 25 | $12.7M | $10.6M | ||
| Q3 25 | $11.6M | $11.7M | ||
| Q2 25 | $10.3M | $7.6M | ||
| Q1 25 | — | $11.8M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | — | $10.4M | ||
| Q2 24 | $10.3M | $8.9M | ||
| Q1 24 | — | $10.4M |
净利润CHRSRENT
| Q4 25 | $-37.6M | $76.5M | ||
| Q3 25 | $-35.5M | $-26.4M | ||
| Q2 25 | $297.8M | $-26.1M | ||
| Q1 25 | — | $-13.4M | ||
| Q4 24 | — | $-18.9M | ||
| Q3 24 | — | $-15.6M | ||
| Q2 24 | $-12.9M | $-22.0M | ||
| Q1 24 | — | $-24.8M |
毛利率CHRSRENT
| Q4 25 | 68.3% | -126.4% | ||
| Q3 25 | 67.8% | -92.3% | ||
| Q2 25 | 66.9% | -168.4% | ||
| Q1 25 | — | -71.2% | ||
| Q4 24 | — | -122.9% | ||
| Q3 24 | — | -98.1% | ||
| Q2 24 | 82.4% | -131.5% | ||
| Q1 24 | — | -93.3% |
营业利润率CHRSRENT
| Q4 25 | -359.9% | -152.8% | ||
| Q3 25 | -383.1% | -171.8% | ||
| Q2 25 | -443.6% | -259.2% | ||
| Q1 25 | — | -65.3% | ||
| Q4 24 | — | -142.7% | ||
| Q3 24 | — | -92.3% | ||
| Q2 24 | -384.9% | -185.4% | ||
| Q1 24 | — | -185.6% |
净利率CHRSRENT
| Q4 25 | -295.3% | 721.7% | ||
| Q3 25 | -307.1% | -225.6% | ||
| Q2 25 | 2903.9% | -343.4% | ||
| Q1 25 | — | -113.6% | ||
| Q4 24 | — | -196.9% | ||
| Q3 24 | — | -150.0% | ||
| Q2 24 | -125.5% | -247.2% | ||
| Q1 24 | — | -238.5% |
每股收益（稀释后）CHRSRENT
| Q4 25 | $-0.34 | $13.65 | ||
| Q3 25 | $-0.31 | $-6.55 | ||
| Q2 25 | $2.57 | $-6.58 | ||
| Q1 25 | — | $-2.72 | ||
| Q4 24 | — | $-4.70 | ||
| Q3 24 | — | $-4.17 | ||
| Q2 24 | $-0.11 | $-6.03 | ||
| Q1 24 | — | $-5.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $172.1M | $50.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $61.0M | $-35.1M |
| 总资产 | $258.3M | $231.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHRSRENT
| Q4 25 | $172.1M | $50.7M | ||
| Q3 25 | $191.7M | $43.6M | ||
| Q2 25 | $237.6M | $70.4M | ||
| Q1 25 | — | $77.4M | ||
| Q4 24 | — | $74.1M | ||
| Q3 24 | — | $76.6M | ||
| Q2 24 | $159.2M | $82.0M | ||
| Q1 24 | — | $84.0M |
总债务CHRSRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $340.6M | ||
| Q1 25 | — | $333.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CHRSRENT
| Q4 25 | $61.0M | $-35.1M | ||
| Q3 25 | $87.8M | $-232.1M | ||
| Q2 25 | $119.8M | $-207.1M | ||
| Q1 25 | — | $-182.5M | ||
| Q4 24 | — | $-171.2M | ||
| Q3 24 | — | $-154.5M | ||
| Q2 24 | $-84.1M | $-141.3M | ||
| Q1 24 | — | $-122.3M |
总资产CHRSRENT
| Q4 25 | $258.3M | $231.0M | ||
| Q3 25 | $516.5M | $219.0M | ||
| Q2 25 | $439.5M | $245.3M | ||
| Q1 25 | — | $240.0M | ||
| Q4 24 | — | $251.6M | ||
| Q3 24 | — | $257.4M | ||
| Q2 24 | $674.9M | $278.4M | ||
| Q1 24 | — | $278.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.7M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CHRSRENT
| Q4 25 | $-19.7M | $-1.4M | ||
| Q3 25 | $-46.3M | $-10.5M | ||
| Q2 25 | $-46.6M | $8.3M | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | $4.7M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | $59.7M | $4.6M | ||
| Q1 24 | — | $-8.0M |
现金转化率CHRSRENT
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
RENT
暂无分部数据
